entertainment -WSS

entertainment

author：comprehensive 2025-10-01 16:38:13 - browse：92846

Immunofluorescence image shows CD4+ (green) and CD8+ (yellow) T cells in the microenvironment of a head and neck squamous cell carcinoma. — This immunofluorescence image shows T cells (in green and yellow) in the microenvironment of a head and neck squamous cell carcinoma. Allen Lab/NCI/NIH

Merus said Tuesday that the combination of its experimental drug petosemtamab with the checkpoint inhibitor Keytruda shrank tumors in 62% of patients with head and neck cancer, according to an interim analysis of an ongoing mid-stage clinical trial.

The new efficacy results, derived from a larger number of patients, look similar to an initial disclosure made last week that triggered a 36% increase in Merus’ stock price.

But the Dutch drugmaker on Tuesday withheld additional information from the study related to the safety and durability of petosemtamab’s tumor responses, pending presentation at the annual meeting of the American Society of Clinical Oncology on June 3.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： BioMarin wins approval for gene therapy to treat hemophilia A

hotspot

WSS

Medicare details structure of new drug price negotiation program

Dozens dead from Maui wildfires: What we know about the victims

Schizophrenia gene found to be linked to cells' energy dysfunction

Drug repurposing or repositioning? The language matters

Psychedelics group wrestles with new pharma identity

Treatments for cramps don't cut it. Why aren't there better options?

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

What does generative AI mean for health care? We asked experts

Mark Cuban is blaming the wrong people for high drug costs

ChatGPT in medicine: STAT answers readers' burning questions

Moonlake's readout produced a cash windfall. Risks remain

Affirmative action in medical school literally saved lives

Affirmative action in medical school literally saved lives

DIEP, the 'gold standard' of breast reconstruction, is under threat

Heart attack and stroke risk calculators need revising

Medicare details structure of new drug price negotiation program

George Santos makes 1st court appearance after pleading not guilty to 13 counts

focus

Affirmative action in medical school literally saved lives

Novo Nordisk touts Wegovy study, but still struggling with supply

Moonlake's readout produced a cash windfall. Risks remain

ChatGPT in medicine: STAT answers readers' burning questions

Patients, digital health players weigh in on FTC's data privacy plan

Dozens dead from Maui wildfires: What we know about the victims

hotspot

focus

hotspot

explore